XML 31 R21.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 3 Months Ended
--- | ---
Sep. 30, 2022
Protein Sciences [Member] |
Notes Tables |
Schedule of restructuring charges | The related first quarter of fiscal 2023 restructuring charges were recorded in the income statement as follows (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Employee | ​ | Asset | ​ | ​
​ |  | severance |  | related and other |  | Total
Selling, general and administrative | ​ | $ | 1,328 | ​ | $ | 842 | ​ | $ | 2,170
​ Restructuring actions, including cash and non-cash impacts, are as follows (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Employee | ​ | Asset | ​ | ​
​ |  | severance |  | related and other |  | Total
Expense incurred in the first quarter of 2023 | ​ | $ | 1,328 | ​ | $ | 842 | ​ | $ | 2,170
Cash payments | ​ | ​ | (420) | ​ | ​ | (431) | ​ | ​ | (851)
Adjustments | ​ | ​ | — | ​ | ​ | (72) | ​ | ​ | (72)
Accrued restructuring actions balances as of September 30, 2022 | ​ | $ | 908 | ​ | ​ | 339 | ​ | ​ | 1,247
​
Diagnostics and Genomics [Member] |
Notes Tables |
Schedule of restructuring charges | Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the year ended June 30, 2022 were recorded within operating income on the income statement as follows (in thousands): ​
: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Employee | ​ | Asset | ​ | ​
​ |  | severance |  | Impairment and other |  | Total
Selling, general and administrative | ​ | $ | 649 | ​ | $ | 750 | ​ | $ | 1,399
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Employee | ​ | Asset | ​ | ​
​ |  | severance |  | Impairment and other |  | Total
Expense incurred in the first quarter of 2022 | ​ | $ | 639 | ​ | $ | 546 | ​ | $ | 1,185
Incremental expense incurred during fiscal 2022 | ​ | ​ | — | ​ | ​ | 242 | ​ | ​ | 242
Cash payments | ​ | ​ | (589) | ​ | ​ | (554) | ​ | ​ | (1,143)
Adjustments(1) | ​ | ​ | (50) | ​ | ​ | (234) | ​ | ​ | (284)
Accrued restructuring actions balances as of June 30, 2022 | ​ | $ | — | ​ | ​ | — | ​ | ​ | —
(1)Adjustments include refinements to our estimated close down costs as well as the impacts from foreign currency exchange.

X
- Definition Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -URI https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4) -URI https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=tech_ProteinSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=tech_DiagnosticsAndGenomicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |